Nearly double the number of patients with advanced non-small cell lung cancer would be eligibile for clinical trial enrollment if a broader set of eligibility criteria proposed by the American Society of Clinical Oncology and Friends of Cancer Research was implemented, according to data presented at the 2019 ASCO Annual Meeting.
Patients with colorectal cancer and liver metastases who underwent laparoscopic surgery had similar long-term rates of overall survival compared with patients who had open liver surgery, according to results of the randomized OSLO-COMET trial. These findings were presented in a press briefing during the 2019 ASCO Annual Meeting.
According to data from the phase II EV-201 study presented at the 2019 ASCO Annual Meeting, 44% of patients with locally advanced or metastatic urothelial cancer achieved responses with enfortumab vedotin. This includes 12% of patients reached a complete response to treatment. Median overall survival time for patients was 11.7 months.
Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses results from the protocol-specified final analysis of the phase III KEYNOTE-048 trial of pembrolizumab (Keytruda) as frontline therapy for recurrent/metastatic head and neck squamous cell carcinoma.
Progression-free survival was significantly improved with the triplet combination of isatuximab, pomalidomide, and low-dose dexamethasone compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to findings from the phase III ICARIA-MM trial presented at the 2019 ASCO Annual Meeting.<br />
A subcutaneous formulation of daratumumab showed similar efficacy to the original intravenous formulation of daratumumab in the phase III COLUMBA trial of patients with relapsed/refractory multiple myeloma. The subcutaenous flat-dose of daratumumab also showed a reduction in the treatment burden, according to results presented at the 2019 ASCO Annual Meeting.
Cemiplimab demonstrated substantial antitumor activity and induced durable responses in patients with locally advanced cutaneous squamous cell carcinoma who were enrolled in the pivotal EMPOWER-CSCC-1 phase II study, and these results were similar to previously reported data in patients with metastatic CSCC enrolled in the same study.
Racial disparities in time to cancer treatment are nearly eliminated since the expansion of Medicaid, according to the results from a study presented at the 2019 ASCO Annual Meeting. Analysis on the impact of the Affordable Care Act Medicaid expansion showed Medicaid was associated with a 6.1 percentage point improvement in timely access to cancer care treatment for African American patients versus 2.1 in white patients.
After passage of the Affordable Care Act, women with ovarian cancer who were pre-medicare-aged were more likely to be diagnosed at an early stage and receive treatment within 30 days of diagnosis compared to prior to the ACA, according to findings presented at the 2019 ASCO Annual Meeting.
Single-agent lurbinectedin induced an overall response rate of 35.2% in the second-line setting for the treatment of patients with small cell lung cancer in a phase II basket trial, presented at the 2019 ASCO Annual Meeting.
Details on a prototype system were released during the 2019 ASCO Annual Meeting by a consortium of cancer care institutions that was designed to use electronic health record systems to provide real-world patient data that could guide research and improve cancer treatment.
According to a study authors performed to call attention to the need to address socioeconomic disparities that influence treatment outcomes, higher incomes and having private insurance were associated with a significantly greater probability of survival for patients with multiple myeloma.
Survival was increased with the treatment of enzalutamide plus standard of care compared with the use of other non-steroidal anti-androgens plus SOC for patients with metastatic hormone-sensitive prostate cancer. Results from an interim analysis of the phase III ENZAMET trial presented at the 2019 ASCO Annual Meeting showed that 80% of men with mHSPC were alive after 3 years with enzalutamide treatment compared with 72%.
The PARP inhibitor olaparib significantly improved progression-free survival in patients with germline BRCA-mutated metastatic pancreatic cancer compared to placebo when used as maintenance therapy in the phase III POLO trial, presented at the 2019 ASCO Annual Meeting.
Karim Fizazi, MD, PhD, professor and head of the GARD Inpatient Unit, at Institut Gustave Roussy, discusses the impact of darolutamide (ODM-201) on pain and quality of life in patients with nonmetastatic castration-resistant prostate cancer.
Updated data from the phase III EORTC 18071 study showed that patients with surgically resected high-risk, stage III melanoma experienced a 25% reduction in the risk of recurrence or death with adjuvant ipilimumab compared with placebo.
Patients with metastatic castration-resistant prostate cancer who received apalutamide plus androgen deprivation therapy had a 33% reduced risk of death compared with patients taking androgen deprivation therapy alone in the phase III TITAN trial. Topline results from the trial were presented at the 2019 ASCO Annual Meeting and simultaneously published in the <em>New England Journal of Medicine.</em>
Overall survival from the KEYNOTE-001 trial in patients with advanced non–small cell lung cancer showed treatment with pembrolizumab monotherapy produced more favorable rates of response at 5 years when compared with historical, pre-immunotherapy standard-of-care regimens.
According to findings from the phase III MONALEESA-7 trial, peri and premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy demonstrated an estimated overall survival rate of 70.2% at 42 months compared with 46% for placebo and endocrine therapy.
Patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer had non-inferior overall survival with frontline pembrolizumab compared with standard chemotherapy, according to results from the phase III KEYNOTE-062 trial.
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, at Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, at Harvard Medical School, highlights key trials in kidney cancer presented at the 2019 ASCO Annual Meeting.
Ahead of the 2019 ASCO Annual Meeting, the American Society of Clinical Oncology announced leaders in the field of oncology who will be recognized during the upcoming annual meeting. The winners of ASCO’s Special Awards and Conquer Cancer’s Women Who Conquer Cancer Mentorship Awards will be acknowledged for their work toward transforming cancer care around the world.
In an interview with <em>Targeted Oncology</em>, experts in gynecology, gastrointestinal, genitourinary, lung, and breast cancers spoke to the significance of the abstracts they are most looking forward to at the 2019 ASCO Annual Meeting.
One-hundred percent of pediatric patients with CNS and solid tumors harboring <em>NTRK1/2/3</em>, <em>ROS1</em>, or <em>ALK</em> gene fusions or mutations achieved objective responses with entrectinib, according to the phase I/Ib STARTRK-NG trial data presented in a press cast ahead of the 2019 ASCO Annual Meeting.
Edwin M. Posadas, MD, medical director, Urologic Oncology Program, co-director, Translational Oncology Program, associate professor, Medicine, Cedars-Sinai Medical Center, discusses key takeaways from the ARAMIS trial of darolutamide in high-risk nonmetastatic castration-resistant prostate cancer.
Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.
Olaparib combined with neratinib may be a novel treatment option for patients with HER2-positive, homologous recombination–proficient ovarian cancer tumors that are resistant to chemotherapy, preclinical findings presented during the 2019 SGO Annual Meeting showed.<br />
Neratinib demonstrated durable responses and disease control and a manageable safety profile in patients with metastatic <em>HER2</em>-mutant cervical cancer, according to results from the ongoing phase II SUMMIT basket trial.
Ursula A. Matulonis, MD, discusses the survival results from an analysis of the QUADRA trial in heavily pretreated patients with recurrent ovarian cancer.
Women with recurrent ovarian cancer treated with the combination of pembrolizumab, bevacizumab, and metronomic cyclophosphamide had a 95% disease control rate and a 40% overall response rate, according to findings from an open-label phase II study presented during the 2019 SGO Annual Meeting.